Ngā Hua Whakamiharo mō te CD7 CAR-T Therapy i roto i te Maimoatanga o te Relapsed/Refractory Peripheral T-Cell Lymphoma i te ASH 2024
I te Hui-ā-Tau 66 o te American Society of Hematology (ASH) 2024, i tū mai i te 7 ki te 10 o Hakihea i San Diego, i whakaatu a Ahorangi Lu Peihua o te Hōhipera Lu Daopei i tētahi whakamātautau haumanu Wāhanga Tuatahi o te rongoā CD7-targeted Chimeric Antigen Receptor T-cell (CAR-T) mō te rongoā i ngā mate pāwera ā-peripheral kua hoki mai/aukati. Lymphoma Pūtau-T (R/R PTCL). He putanga nui tēnei i roto i te rongoā i ngā mate pukupuku pūtau-T, ina hoki he iti noa ngā kōwhiringa rongoā e wātea ana, ā, he iti ake te whai huatanga.
E mōhiotia ana te R/R PTCL mō tōna āhua kino, inā koa mō ngā tūroro kua maha ngā momo maimoatanga kua pā ki a rātou, tae atu ki te whakawhitinga pūtau take hematopoietic allogeneic (allo-HSCT). Ahakoa tēnei, kua whakaatuhia e te rongoā CD7 CAR-T, inā koa te rongoā pūtau NS7CAR-T i whakawhanakehia e te tīma a Ahorangi Lu, he hua whakatenatena i roto i te rongoā i ngā tūroro me te CD7-positive R/R PTCL. I roto i tēnei whakamātautau, e rima ngā tūroro katoa, mai i te 39 ki te 60 tau te pakeke, me ngā wāhanga matatau o te R/R PTCL i whakaurua i waenga i a Paenga-whāwhā 2021 me Noema 2023. E ono ngā momo maimoatanga o mua i pā ki ēnei tūroro, tae atu ki tētahi kēhi me te hītori o te whakawhitinga pūtau take autologous.
He pai ngā hua: i roto i te wā aroturuki toharite o te 234 rā, 60% o ngā tūroro i tutuki te murunga katoa (CR), ā, kotahi te tūroro i tutuki te murunga wāhanga (PR). He mea nui, i whakaatuhia e te rongoā he nui te tipu me te pumau o ngā pūtau CAR-T i roto i ngā tūroro, me te taumata teitei toharite o ngā pūtau CAR-T i eke ki te 93.5% te whai huatanga. He mea nui, kāore he pānga kino nui pērā i te paitini roro, ā, he ngawari te mate tuku cytokine (CRS), kotahi anake te tūroro i pāngia e te CRS taumata II. I taea te whakahaere i te kōtaha haumaru, kāore he paitini kino i kitea.
E whakaatu ana ngā rangahau a Ahorangi Lu i te kaha o te rongoā CD7 CAR-T hei whakarerekētanga nui i roto i te rongoā i ngā mate pukupuku pūtau-T, inā koa i roto i ngā tūroro he iti noa iho, kāore rānei he kōwhiringa rongoā e toe ana. Haunga ngā hua pai i roto i te PTCL, kua eke te tīma a Ahorangi Lu ki te whai huatanga nui i roto i te rongoā i te mate pukupuku lymphoblastic acute cell-T (T-ALL) me te lymphoma lymphoblastic cell-T (T-LBL), me te tata ki te 95% te tere whakaora katoa i roto i te rōpū o te 60 tūroro. I runga i ēnei hua, kei te whakawhānui ake te tīma i ā rātou rangahau ki ētahi atu mate pukupuku toto pērā i te mate pukupuku myeloid acute (AML), me ngā raraunga wawe e whakaatu ana i te 70% te tere whakaora katoa i roto i ngā tūroro AML CD7-pai.
Ahakoa ēnei hua pai, e whakanui ana a Ahorangi Lu i te hiranga o te whakakotahi i te rongoā CD7 CAR-T me te allo-HSCT hei whakapai ake i ngā putanga mō te wā roa. Ko te rerekētanga o ngā mate pukupuku pūtau-T e hiahia ana ki tētahi rautaki maimoatanga whānui hei whakanui ake i ngā tūponotanga o te murunga roa me te whakaora pea. Kei te whakapai tonu te tīma i tā rātou huarahi me te whakawhānui ake i ngā tohu rongoā mō te rongoā CD7 CAR-T.
Ko te mahi matua a Ahorangi Lu, kua rongoatia kētia e ia neke atu i te 300 ngā tūroro ki te rongoā CD7 CAR-T, he taahiraa nui ki mua i roto i te rongoā mate pukupuku pūtau-T. I te heke mai, e whakapau kaha ana te tīma ki te whakahaere i ētahi atu whakamātautau haumanu me te whakapai ake i ngā tikanga rongoā pūtau-T, kia nui ake ai ngā tūroro ka whai hua mai i tēnei huarahi hou.
E whakaatu ana tēnei whakamātautau Wāhanga Tuatahi whai hua i ASH 2024 i te pūmanawa o te rongoā CD7 CAR-T hei rohe hou i roto i te mate pukupuku toto, e tuku ana i te tumanako mō ngā tūroro he mate kāore i taea te rongoā i mua.